<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67210">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02003339</url>
  </required_header>
  <id_info>
    <org_study_id>2012-JE-CHC-Pron</org_study_id>
    <secondary_id>2012-A00972-41</secondary_id>
    <nct_id>NCT02003339</nct_id>
  </id_info>
  <brief_title>Interest of Functional MRI (Magnetic Resonance Imagery) (in Patients Suffering From Hepatocellular Carcinoma and Treated With Yttrium</brief_title>
  <acronym>ICY</acronym>
  <official_title>Pilot Prospective Study on Interest of Functional MRI in Early Assessment of Radioembolization Efficiency in Patients Suffering From Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center Eugene Marquis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Center Eugene Marquis</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For patients who are suffering from hepatocellular carcinoma and are treated with
      radioembolization, the purpose of this study is to analyse parameters of functional MRIs
      that are modified early and to detect parameters that vary significantly after treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Modifications of functional MRI parameters</measure>
    <time_frame>Before radioembolization and up to 6 months after radioembolization</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between functional MRIs parameters and tumoral response</measure>
    <time_frame>Measured 6 months after radioembolization</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of alternative morphological response criteria : EASL (European Association for study of the liver)  and mRECIST (m response evaluation criteria in solid tumor) criteria. Link with RECIST response.</measure>
    <time_frame>2 and 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of VEGF (vascular endothelial growth factor) release</measure>
    <time_frame>From day 0 to 2 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>RMIs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Additional RMIs</intervention_name>
    <arm_group_label>RMIs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Early, intermediate, advanced, non metastatic Hepatocellular Carcinoma. Indication
             for radioembolization validated after pluridisciplinary committee meeting.

          -  Isolated target on initial imagery (invasive hepatocellular carcinoma   excluded)

          -  WHO (World Health organization) Performance status: 0, 1 or 2

          -  If cirrhosis, Child A score with total bilirubin less than 30 micromoles per liter

          -  Creatinine clearance more or equal to 30 mL/min

          -  Patient informed and consent signature obtained

        Exclusion Criteria:

          -  Invasive hepatocellular carcinoma without any isolated tumor

          -  Disease needing 2 injections of Therasphere

          -  Thrombosis extending into the porta(thrombosis of one of left or right branch
             authorized), extra hepatic metastasis

          -  Previous treatment by chemoembolization, radiofrequency less than 3 months before
             radioembolization

          -  No antiangiogenic concomitant treatment, 15 days before and 15 days after
             radioembolization, including Sorafenib

          -  Associated disease which could prevent patient from receiving treatment

          -  RMI contre-indication(particle or metal prosthesis, pacemaker, claustrophobia) or
             contrast product contre-indication (allergy)

          -  Patient already participating in an other therapeutic trial with an experimental drug

          -  Pregnant or childbearing potential women or breastfeeding women

          -  minors, persons deprived of liberty or protected adults (maintenance of justice,
             guardianship or supervision) Unable to comply with trial medical follow-up for
             geographical, social or psychological reasons

          -  Unable to sign an informed consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julien EDELINE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Eugène Marquis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julien EDELINE, MD</last_name>
    <email>j.edeline@rennes.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien EDELINE, MD</last_name>
      <email>j.edeline@rennes.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Julien EDELINE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>December 2, 2013</lastchanged_date>
  <firstreceived_date>November 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Stress, Psychological</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
